UVEITIS MARKET ANALYSIS, MARKET SIZE, EPIDEMIOLOGY, LEADING COMPANIES AND COMPETITIVE ANALYSIS

UVEITIS MARKET ANALYSIS, MARKET SIZE, EPIDEMIOLOGY, LEADING COMPANIES AND COMPETITIVE ANALYSIS

“”Uveitis – Market Insights, Epidemiology, and Market Forecast-2030″”

(Albany, US) DelveInsight has launched a new report on Uveitis Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Uveitis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Uveitis , historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts of the Report:

  1. The therapeutic market of Uveitis in the seven major markets was USD 1,045.9 million in 2017.
  2. The total prevalent cases of Uveitis in the US were observed to be 357,791 in 2017.
  3. In 2017, it was found that there were 28,111 diagnosed cases of infectious uveitis in the

 United States.

  1. In 2017, it was found that there were 293,901 diagnosed cases of non-infectious uveitis in the United States.

 

Key benefits of the Report

1. Uveitis market report covers a descriptive overview and comprehensive insight of the Uveitis epidemiology and Uveitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Uveitis market report provides insights on the current and emerging therapies. 

3. Uveitis market report offers a global historical and forecasted market covering drug outreach in 7 MM.

4. Uveitis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Uveitis market.

 

Request for Sample Pages:  https://www.delveinsight.com/sample-request/uveitis-market?utm_source=ABNewswire&utm_medium=Ankit-PressRelease&utm_campaign=Uveitis%20Market

 

 “According to DelveInsight, the majority of cases of Uveitis are female as compared to male. There were total 163,260 female and 158,752 male cases of Uveitis in 2017 in the United States.”

 

Prevent Blindness Organization defines Uveitis as, a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.

Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (Panuveitis) implies inflammation of the entire uveals tract.

Symptoms of acute forms of uveitis include ocular pain, photophobia, lacrimation, and redness. Uveitis is most often idiopathic but has been associated with traumatic, inflammatory, and infectious processes.

               

Some of the key companies working on Uveitis are:

  • Santen
  • EyeGate Pharmaceuticals
  • Sanofi
  • Oculis Pharma
  • Clearside Biomedical

And Many Others.

The launch of the emerging therapies is expected to significantly impact the Uveitis treatment scenario in the upcoming years:-

 Drugs Covered:

  • Sirolimus
  • EGP-437
  • Sarilumab
  • LME636 (OCS-02)
  • Suprachoroidal CLS-TA(Triamcinolone Acetonide)

And Many Others.

 

Request for Sample Pages:  https://www.delveinsight.com/sample-request/uveitis-market?utm_source=ABNewswire&utm_medium=Ankit-PressRelease&utm_campaign=Uveitis%20Market

 

Table of Contents:

1. Key Insight

2. Uveitis Market Overview at a Glance

2.1. Market Share (%) Distribution of Uveitis in 2017

2.2. Market Share (%) Distribution of Uveitis in 2030

3. Disease Background and Overview: Uveitis

3.1. Introduction

3.2. Classification of Uveitis

3.3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis

3.4. The Standardization of Uveitis Nomenclature (SUN) Working Group

3.5. Symptoms of Uveitis

3.6. Pathophysiology

3.7. Etiology of Uveitis

3.8. Diagnosis of Uveitis

3.8.1. American Academy of Family Physicians

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Prevalent Population of Uveitis in the 7MM

4.3. Diagnosed Prevalent Population of Uveitis in the 7MM

4.4. Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM

5. United States-Epidemiology of Uveitis

5.1. Assumptions and Rationale

5.2. Total Prevalent Population of Uveitis in the United States

5.3. Diagnosed Prevalent Population of Uveitis in the United States

5.4. Gender-Specific Diagnosed Prevalent Population of Uveitis in United States

5.5. Age-Specific Diagnosed Prevalent Population of Uveitis in United States

5.6. Type Specific Diagnosed Prevalent Population of Uveitis in United States

5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

5.7.1. Diagnosed prevalent cases of Anterior noninfectious Uveitis (aNIU) in the United States

5.7.2. Diagnosed prevalent cases of Nonanterior NIU (Posterior Segment) or NIPU in the US

5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the US

6. EU-5 Epidemiology of Uveitis

6.1. Germany

6.1.1. Assumptions and Rationale

6.1.2. Prevalent Population of Uveitis in Germany

6.1.3. Diagnosed Prevalent Population of Uveitis in Germany

6.1.4. Gender Specific Diagnosed Prevalence of Uveitis in Germany

6.1.5. Age Group Specific Diagnosed Prevalence of Uveitis in Germany

6.1.6. Type Specific Diagnosed Prevalence of Uveitis in Germany

6.1.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

6.1.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany

6.2. France

6.2.1. Assumptions and Rationale

6.2.2. Prevalent Population of Uveitis in France

6.2.3. Diagnosed Prevalent Population of Uveitis in France

6.2.4. Gender Specific Diagnosed Prevalence of Uveitis in France

6.2.5. Age Specific Diagnosed Prevalence of Uveitis in France

6.2.6. Type Specific Diagnosed Prevalence of Uveitis in France

6.2.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

6.2.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France

6.3. Italy

6.3.1. Assumptions and Rationale

6.3.2. Prevalent Population of Uveitis in the Italy

6.3.3. Diagnosed Prevalent Population of Uveitis in Italy

6.3.4. Gender Specific Diagnosed Prevalence of Uveitis in Italy

6.3.5. Age Specific Diagnosed Prevalence of Uveitis in Italy

6.3.6. Type Specific Diagnosed Prevalence of Uveitis in Italy

6.3.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

6.3.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy

6.4. Spain

6.4.1. Assumptions and Rationale

6.4.2. Prevalent Population of Uveitis in the Spain

6.4.3. Diagnosed Prevalent Population of Uveitis in Spain

6.4.4. Gender Specific Diagnosed Prevalence population of Uveitis in Spain

6.4.5. Age Specific Diagnosed Prevalence of Uveitis in Spain

6.4.6. Type Specific Diagnosed Prevalence of Uveitis in Spain

6.4.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain

6.4.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain

6.5. United Kingdom

6.5.1. Assumptions and Rationale

6.5.2. Prevalent Population of Uveitis in the UK

6.5.3. Diagnosed Prevalent Population of Uveitis in United Kingdom

6.5.4. Gender Specific Diagnosed Prevalence of Uveitis in UK

6.5.5. Age Specific Diagnosed Prevalence of Uveitis in UK

6.5.6. Type Specific Diagnosed Prevalence of Uveitis in UK

6.5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK

6.5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK

7. Japan

7.1. Assumptions and Rationale

7.2. Prevalent Population of Uveitis in the Japan

7.3. Diagnosed Prevalent Population of Uveitis in the Japan

7.4. Gender Specific Prevalence of Uveitis in Japan

7.5. Age Specific Prevalence of Uveitis in Japan

7.6. Type Specific Prevalence of Uveitis in Japan

7.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan

7.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan

8. Treatment of Uveitiss

8.1. Treatment Algorithm

8.2. First Line of Therapy: Corticosteroids

8.3. Second Line of Therapy: Immunosuppressants

8.4. Third Line of Therapy: Biologics

8.5. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis:

Fundamentals of Care for Uveitis (FOCUS) Initiative

9. Unmet Needs

10. Marketed Drugs

10.1. Key Cross Competition

10.2. Durezol: Sirion Therapeutics

10.2.1. Product Description

10.2.2. Regulatory Milestones

10.2.3. Advantages & Disadvantages

10.2.4. Safety and Efficacy

10.2.5. Product Profile

10.3. Triesence: Novartis

10.3.1. Drug Description

10.3.2. Regulatory Milestones

10.3.3. Advantages & Disadvantages

10.3.4. Safety and Efficacy

10.3.5. Product Profile

10.4. Retisert: Valeant Pharmaceuticals International Inc

10.4.1. Drug Description

10.4.2. Regulatory Milestones

10.4.3. Advantages & Disadvantages

10.4.4. Safety

10.4.5. Efficacy

10.4.6. Product Profile

10.5. Ozurdex: Allergan plc

10.5.1. Drug Description

10.5.2. Regulatory Milestones

10.5.3. Advantages & Disadvantages

10.5.4. Efficacy

10.5.5. Safety

10.5.6. Product Profile

10.6. Humira: AbbVie Inc.

10.6.1. Drug Description

10.6.2. Regulatory Milestones

10.6.3. Advantages & Disadvantages

10.6.4. Safety and Efficay

10.6.5. Product Profile

10.7. Yutiq: Eyepoint Pharmaceuticals

10.7.1. Product Description

10.7.2. Clinical Development

10.7.3. Advantages & Disadvantages

10.7.4. Safety and Efficacy

10.7.5. Product Profile

10.8. Tobradex: Alcon Laboratories

10.8.1. Product Description

10.8.2. Other Developmental Activities

10.8.3. Product Profile

10.9. Acthar: Mallinckrodt

10.9.1. Product Description

10.9.2. Other Developmental Activities

10.9.3. Advantages and Disadvantages

10.9.4. Safety and Efficacy

10.9.5. Product Profile

10.10. Iluvien: Alimera Sciences

10.10.1. Product Description

10.10.2. Other Developmental Activities

10.10.3. Clinical Development

10.10.4. Clinical Trials Information

10.10.5. Safety and Efficacy

10.10.6. Product Profile

11. Emerging Drugs Analysis

11.1. Key Cross Competition

11.2. ADX-102: Aldeyra Therapeutics Inc.

11.2.1. Product Description

11.2.2. Advantages & Disadvantages

11.2.3. Clinical Development

11.2.4. Safety and Efficacy

11.2.5. Product Profile

11.3. Sirolimus: Santen

11.3.1. Product Description

11.3.2. Regulatory Milestones

11.3.3. Advantages & Disadvantages

11.3.4. Clinical Development

11.3.5. Safety and Efficacy

11.3.6. Product Profile

11.4. EGP-437: EyeGate Pharmaceuticals

11.4.1. Product Description

11.4.2. Regulatory Milestones

11.4.3. Advantages & Disadvantages

11.4.4. Clinical Development

11.4.5. Safety and Efficacy

11.4.6. Product Profile

11.5. Suprachoroidal CLS-TA: Clearside Biomedical, Inc.

11.5.1. Product Description

11.5.2. Clinical Development

11.5.3. Safety and Efficacy

11.5.4. Product Profile

11.6. Sarilumab: Sanofi Aventis

11.6.1. Product Description

11.6.2. Product Development Activities

11.6.3. Advantages and Disadvantages

11.6.4. Clinical Development

11.6.5. Safety and Efficacy

11.6.6. Product Profile

11.7. LME636 (OCS-02): Oculis Pharma

11.7.1. Product Description

11.7.2. Other development activities

11.7.3. Clinical Development

11.7.4. Safety and Efficacy

11.7.5. Product Profile

11.8. LFG316: Novartis

11.8.1. Product Description

11.8.2. Other development activities

11.8.3. Clinical Development

11.8.4. Safety and Efficacy

11.8.5. Product Profile

11.9. Abatacept (Orenica): Bristol-Myers Squibb Company

11.9.1. Product Description

11.9.2. Clinical Development

11.9.3. Safety and Efficacy

11.9.4. Product Profile

11.10. EYS606: Eyevensys

11.10.1. Product Description

11.10.2. Other development activities

11.10.3. Clinical Development

11.10.4. Safety and Efficacy

11.10.5. Product Profile

12. Uveitis: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Uveitis in the 7MM

12.3. Market Size of Uveitis by Therapies in the 7MM

13. United States: Market Outlook

13.1. Total Market size of Uveitis

13.2. Uveitis Market Size by Therapies

14. EU5: Market Outlook

14.1. Germany Market Size

14.1.1. Total Market size of Uveitis

14.1.2. Uveitis Market Size by Therapies

14.2. France Market Size

14.2.1. Total Market size of Uveitis

14.2.2. Uveitis Market Size by Therapies

14.3. Italy Market Size

14.3.1. Total Market size of Uveitis

14.3.2. Uveitis Market Size by Therapies

14.4. Spain Market Size

14.4.1. Total Market size of Uveitis

14.4.2. Uveitis Market Size by Therapies

14.5. United Kingdom Market Size

14.5.1. Total Market size of Uveitis

14.5.2. Uveitis Market Size by Therapies

15. Japan: Market Outlook

15.1. Japan: Market Size

15.1.1. Total Market size of Uveitis

15.1.2. Uveitis Market Size by Therapies

16. Market Drivers

17. Market Barriers

18. Appendix

19. Report Methodology

19.1. Sources Used

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

Related Reports:

Uveitis – Pipeline Insights, 2020

The Uveitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Uveitis across the complete product development cycle, including all clinical and nonclinical stages.

Uveitis – Epidemiology Forecast to 2030

The Uveitis epidemiology covered in the report provides historical as well as forecasted Uveitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/